A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015

BACKGROUND: Sorafenib is an oral tyrosine kinase inhibitor that is indicated for advanced hepatocellular carcinoma (HCC). The aim of the present study was to determine the clinical outcomes of HCC patients receiving sorafenib in real-life clinical setting in comparison with formal clinical trials. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chi-Chun, Chen, Hsin-Yi, Chang, Ruei-Hsin, Liao, Pen-An, Lien, Heng-Hui, Hung, Chih-Sheng, Yang, Sien-Sing, Hu, Jui-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349409/
https://www.ncbi.nlm.nih.gov/pubmed/30774305
http://dx.doi.org/10.2147/DDDT.S191334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349409/
https://www.ncbi.nlm.nih.gov/pubmed/30774305
http://dx.doi.org/10.2147/DDDT.S191334

Ejemplares similares